Background
Unipolar depression is a mental disorder of paramount importance. Worldwide the lifetime prevalence is estimated to be between 10 and 15% [
1]. It is projected to become the leading cause of burden of disease worldwide by 2030 [
2]. Core symptoms of depression are depressed mood, anhedonia, and a lack of drive. Depression is associated with an increased risk of comorbidities [
3] and cardiovascular mortality [
4]. It is also associated with lower cardiorespiratory fitness [
5], an independent risk factor for cardiovascular mortality in healthy individuals [
6].
There is a plethora of research concerning treatments for depression. Psychotherapy, pharmacotherapy or a combination of both are the primary treatments for depression according to guidelines [
7,
8]. Meta-analytic data show moderate to large effect sizes for pharmacotherapy (0.35), psychotherapy (0.37), and combined therapy (0.74) when compared to placebo [
9]. However, the STAR*D trial investigating four treatment steps in over 4000 patients concluded that only two-thirds of people treated for depression with pharmacotherapy, cognitive behavioral therapy, or both were in remission after treatment [
10]. Moreover, the majority of patients tend to prefer non-pharmacological treatments for insomnia [
11,
12] and depression [
13]. Hence, there is a need for further adjuvant non-pharmacological treatment options.
Insomnia encompasses problems initiating or maintaining sleep with daytime impairments [
14]. Another symptom may be non-restorative sleep. The current state of knowledge suggests that hyperarousal [
15,
16], as well as sleep reactivity [
17], are core etiological factors of insomnia. Hyperarousal can be cognitive (e.g., rumination, dysfunctional beliefs), emotional (emotional reactivity), cortical (beta activity in sleep EEG), or physiological (e.g., metabolic rate, heart rate variability).
There is an abundance of research related to insomnia treatments. Cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy are currently considered first- and second-line therapies for insomnia (regardless whether comorbidities are present or not) [
17,
18]. CBT-I is very effective [
19]. However, the number of trained specialists considerably limits access to this treatment. Pharmacologic agents such as benzodiazepines, non-benzodiazepines, and sedating antidepressants are another, arguably more frequently administered therapy for insomnia. However, pharmacotherapy has multiple limitations: (1) effects have been shown to be statistically significant but of limited clinical relevance [
20,
21], (2) dosages and (3) prescription duration frequently exceed recommendations of health agencies [
22,
23] (especially in patients with comorbidities [
24,
25]), (4) it potentially has severe adverse effects [
26‐
28], and (5) patients often prefer non-pharmacological therapies [
11,
29,
30]. Therefore, there is a need to develop further non-pharmacological treatments.
Insomnia is a highly relevant symptom of depression. Depending on the methodological approach, studies have found 25–90% prevalence rates of insomnia in people with depression [
31,
32]. Longitudinal studies have repeatedly found a bidirectional link between insomnia and depression [
33‐
36]. Insomnia is of prognostic relevance. It negatively affects the disease trajectory [
37], is the most frequent residual symptom after treatment response or remission [
31,
38,
39], increases the probability of relapse [
37,
40,
41], and is an independent risk factor for suicide [
42,
43] as well as adverse somatic outcomes, particularly cardiovascular disease [
44]. Insomnia has considerable economic cost. Individuals who have insomnia are at higher risk for work presenteeism [
45,
46] and absenteeism [
47] with higher direct costs per short-term absence [
48]. Sleep problems are also associated with more work injuries [
49]. Insomnia increases the risk of ending employment prematurely [
50] and increases the risk of disability retirement due to depression [
51].
Insomnia of depressed individuals has been neglected in research, despite its known relevance. Until approximately one decade ago, a central etiological distinction was made between ‘organic’ and ‘psychogenic’ or ‘primary’ and ‘secondary’ insomnia [
52]. However, this distinction has been challenged because, among other reasons, there is often a lack of evidence for a mechanistic distinction between primary and secondary insomnia [
52]. Therefore, a paradigm shift has become apparent, recommending specific treatments for comorbid insomnia. This paradigm shift might explain why, until recently, most trials have focused on patients with insomnia without any comorbidities.
Aerobic exercise is a viable candidate for the treatment of insomnia in patients for depression. Meta-analyses have shown a positive impact of acute and chronic exercise in healthy individuals with small to moderate effect sizes [
53,
54]. Meta-analyses focusing on individuals with at least mild insomnia but no comorbidities have found a moderate effect of chronic aerobic exercise on sleep quality [
54‐
56]. Aerobic exercise has further positive effects such as improving depressive symptoms [
57] and cardiorespiratory fitness [
58]. The latter is especially relevant for the reduction of cardiovascular risk [
6].
Current sleep hygiene recommendations, which are also relevant for depression, lack feasibility. In particular, they state that exercise should not be performed after 2 pm [
59]. This time constraint presents a considerable limitation since many people can only accommodate aerobic exercise in the late afternoon or evening. Even more so this may be limiting for patients with morning depression who may feel more energetic to exercise in the afternoon [
60]. However, a recent meta-analysis has found equivocal effects of exercise performed in the afternoon or evening in healthy individuals [
54]. In healthy individuals, effects of a single evening bout of aerobic exercise on nocturnal heart rate variability seem to depend on intensity, duration, and timing relative to sleep but do not seem to alter subjective sleep quality [
61,
62]. One trial has investigated the effects of acute aerobic exercise in chronic primary insomniacs, showing moderate to large effect sizes for shortened sleep onset latency, improved sleep efficiency, and longer total sleep time [
63].
Rationale and hypotheses
An extensive literature search yielded no randomized controlled trials investigating the acute effects of exercise on sleep in patients with depression. Several studies concerned with chronic effects are available, and we will summarize these in our upcoming systematic review and network meta-analysis (PROSPERO ID 115705, registration not published yet). Considering this gap in the literature and the uncertainty concerning the effects of exercise performed in the afternoon on sleep in patients with depression, a trial on this topic is of high clinical importance.
We hypothesize that an acute bout of aerobic exercise improves 1) sleep efficiency [
54,
63], 2) sleep continuity [
63], 3) sleep architecture [
54], 4) subjective sleep quality [
64], 5) daytime sleepiness [
65], 6) nocturnal blood pressure [
66], 7) pre-sleep arousal, and 8) pre- and post-sleep heart-rate variability. We expect no effect on 9) nocturnal heart rate variability [
62] and 10) the frequency and severity of adverse events [
64].
This paper presents the design and protocol for the trial according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement [
67] (Additional file
1).
Discussion
The goal of this two-arm parallel group, individually randomized, single-blind, controlled trial is to assess the superiority of an acute bout of aerobic exercise compared to no intervention in improving the subsequent night’s sleep efficiency in patients with a primary diagnosis of depression. To the knowledge of the authors, this is the first trial to investigate the acute effects of exercise on sleep in this population.
The main strength of this study is the objective measurement of sleep. Moreover, multiple secondary outcomes were carefully selected to provide clinicians, patients, and policy makers with a comprehensive picture of the effects this intervention may have. Explicit inclusion of patients with comorbidities should enhance the external validity of this study. Accordingly, we provide extensive baseline characterization.
The main limitation of this trial is the restricted polysomnographic EEG montage. More detailed analyses, such as spectral EEG analysis, will therefore not be possible. Extensive discussions in our research group resulted in an explicit trade-off between the patients’ discomfort (number of EEG channels) and feasibility of recruitment. The restricted EEG montage will help to recruit the necessary number of patients in an adequate period in this clinical setting. The pre-selection of patients who are treated in this rehabilitation clinic might pose a further limitation. Extensive baseline characterization will help readers identify limits to external validity. Patients cannot be blinded against allocation in exercise trials. We try to overcome this limitation through various measures (see above).
There is compelling evidence for the effectiveness of various therapies for both insomnia and depression. Nevertheless, many of these therapies have shortcomings. Development of further therapeutic options, which can be administered in addition to these therapies, are therefore needed. Current literature suggests that acute aerobic exercise might improve both depression and insomnia. Although chronic aerobic exercise is included in sleep hygiene recommendations, there is uncertainty concerning the acute effects of aerobic exercise on sleep in patients with depression. This trial aims to close this gap in the literature as well as to help the increasing number of patients with depression.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.